InspireMD, Inc.

NasdaqCM NSPR

InspireMD, Inc. EBT Margin for the year ending December 31, 2023: -319.92%

InspireMD, Inc. EBT Margin is -319.92% for the year ending December 31, 2023, a 10.40% change year over year. EBT Ratio (Earnings Before Tax Ratio) is the fraction of earnings before taxes to total revenue, indicating the company's profitability before the impact of tax expenses.

InspireMD, Inc. EBT Margin for the year ending December 31, 2022 was -357.05%, a -7.91% change year over year.
InspireMD, Inc. EBT Margin for the year ending December 31, 2021 was -330.88%, a 21.99% change year over year.
InspireMD, Inc. EBT Margin for the year ending December 31, 2020 was -424.14%, a -57.57% change year over year.
InspireMD, Inc. EBT Margin for the year ending December 31, 2019 was -269.17%, a -33.88% change year over year.

Key data

Date	EBT Margin	Net Income Margin	EBITDA Margin	EBIT Margin

NasdaqCM: NSPR

InspireMD, Inc.

CEO	Mr. Marvin L. Slosman
IPO Date	April 12, 2011
Location	Israel
Headquarters	4 Menorat Hamaor Street
Employees	65
Sector	Health Care
Industries Medical Instruments Biotechnology Pharmaceuticals

Description

InspireMD, Inc., a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system for use in carotid artery applications; and MGuard Prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions, as well as bypass surgery. It is also developing PVGuard, a MicroNet mesh sleeve and self-expandable stent for use in peripheral vascular applications. The company sells its products through local distributors. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.

Key trends

Past 5 years